Experimental investigation of antibody-mediated clearance mechanisms of amyloid-beta in CNS of Tg-SwDI transgenic mice.
Novel amyloid precursor protein transgenic mice, which contain the Swedish as well as the vasculotropic Dutch and Iowa mutations (Tg-SwDI), were used to investigate the mechanisms of antibody-mediated clearance of amyloid-beta (Abeta) from the brain. Export of the Abeta-DI peptide across the blood-brain barrier is severely reduced because of the vasculotropic mutations. Therefore, antibody-mediated clearance of Abeta-DI is dependent on antibodies entering the brain. In this report, we immunized Tg-SwDI mice with various peptide antigens, including Abeta40-DI, Abeta42, and an Abeta epitope vaccine. Immunization of Tg-SwDI mice with substantial cortical diffuse and vascular fibrillar deposits failed to promote clearance of parenchymal or vascular amyloid deposits. We then immunized young Tg-SwDI mice before the accumulation of Abeta and saw no evidence that anti-Abeta antibodies could diminish deposition of parenchymal or vascular amyloid deposits. However, injection of anti-Abeta antibodies, affinity-purified from immunized Tg-SwDI mice, into the hippocampus induced a rapid clearance of diffuse Abeta deposits but not vascular amyloid deposits. These results further support the "peripheral sink hypothesis" as a legitimate mechanism of antibody-mediated clearance of Abeta when the blood-brain barrier remains intact. Thus, approaches that deliver immunotherapy to the brain may be more effective at clearing Abeta than immunization strategies in which the majority of the antibodies are in the periphery.
The Institute for Brain Aging and Dementia, University of California, Irvine, Irvine, California 92697-4540, USA.
Vitaly
V
Vasilevko
Feng
F
Xu
Mary Lou
ML
Previti
William E
WE
Van Nostrand
David H
DH
Cribbs
D016229:Amyloid beta-Peptides / Q000276:immunology* / Q000378:metabolism*; D000818:Animals; D000906:Antibodies / Q000378:metabolism / Q000502:physiology*; D001812:Blood-Brain Barrier / Q000276:immunology / Q000378:metabolism; D002490:Central Nervous System / Q000276:immunology* / Q000378:metabolism / Q000473:pathology*; D007167:Immunotherapy / Q000379:methods; D008657:Metabolic Clearance Rate / Q000502:physiology; D051379:Mice; D008822:Mice, Transgenic
D016229:Amyloid beta-Peptides; D000906:Antibodies